Gaithersburg, United States
Altimmune, Inc., founded in 1997, is a promising player in the biopharmaceutical sector, carving a niche in the treatment of liver-related diseases. Describing themselves as a "Late clinical-stage biotech working to improve the lives of those living with serious liver diseases," they focus on developing advanced therapies that can potentially transform patient care.
Their lead program showcases a unique dual-action therapy targeting glucagon and GLP-1 receptors. This approach is specifically designed for conditions like metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). This innovative treatment underscores their commitment to addressing complex health challenges.
Backing their vision, Altimmune, Inc. secured a Post IPO Debt investment in May 2025, from Hercules Capital, indicating strong investor confidence in their potential to make significant advances in biopharmaceuticals. Their continued focus on late-stage clinical research positions them as a company to watch for breakthrough developments in liver care.
Madrigal Pharmaceuticals
GENFIT
